Warsaw, Indiana-based orthopedic device company Nextremity Solutions Inc. has announced plans to create up to 111 new jobs by the end of 2024.
Nextremity Solutions Expanding, Adding 111 Jobs
1 min read Premium comments
Secondary#lakelandtechnology#nextremitysolutions
Such growth would represent a near quintupling from its current 24 associates. It will commence hiring for the new positions over the coming months. New positions will in both the product development and manufacturing departments.
This announcement comes after Nextremity Solutions’ acquisition of Lakeland Technology Inc. earlier this year. An ISO 13485 certified contract manufacturer, Lakeland Technology’s services include manufacturing implants, instrument packaging, and complex assembly builds.
Nextremity Solutions will be growing in a new location at 1195 Polk Drive in Warsaw Technology Park. The Indiana Economic Development Corporation (IEDC) designated Warsaw Technology Park a Certified Technology Park. One of only 24 locations with such certification, Warsaw Technology Park houses the Ivy Tech Warsaw campus.
Nextremity Solutions is investing more than $4.5 million in creating its new facility from a shell building. The facility will house both its product development and manufacturing operations. Employees are expected to begin moving into the new location by the end of 2020. Management plans to have construction completed by April 2021.
Nextremity Solutions President and CEO Rod K. Mayer commented, “This is such an exciting time for our team at Nextremity Solutions as we expand our capabilities to create, manufacture and deliver innovative solutions to our strategic alliance partners and to other orthopedic companies.”
Mayer continued, “The shell building provides the ideal location for us as we create a synergistic partnership with Lakeland Technology going forward.”
Nextremity Solutions can receive up to $1.6 million in conditional tax credits and up to $100,000 in training grants from the IEDC. These credits and grants are performance-based and tied to Nextremity Solutions successfully filling positions. Nextremity Solutions may receive additional locally based incentives.
For OTW’s other coverage of Nextremity Solutions see “FDA Clears Nextremity Solutions’ Midfoot Fusion System.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.